Evaluation of microvascular density in tumors: Pro and contra

Histology and Histopathology

Volumn 23, Issue 5, 2008, Pages 601-607

  Nico, Beatrice ^a   Benagiano, Vincenzo ^a   Mangieri, Domenica ^a   Maruotti, Nicola ^b   Vacca, Angelo ^a   Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Angiogenesis; Endothelial cell; Microvascular density; Tumor growth

Indexed keywords

BIOLOGICAL MARKER; CD31 ANTIGEN;

CHEMISTRY; HUMAN; METABOLISM; MICROCIRCULATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; REVIEW; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANTIGENS, CD31; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; MICROCIRCULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 40349089806     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Alexandrakis M.G., Passam F.H., Dambaki C., Pappa C.A. and Stathopoulos E.N. (2004). The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J. Clin. Pathol. 57, 856-860.
2. Barbareschi M., Gasparini G., Morelli L., Forti S. and Dalla Palma P. (1995). Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res. Treat. 36, 181-192.
3. Bossi P., Viale G., Lee A.K., Alfano R., Coggi G. and Bosari S. (1995). Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 55, 5049-5053.
4. Boyle R.G. and Travers S. (2006). Hypoxia: targeting the tumour. Anticancer Agents Med. Chem. 6, 281-286.
5. Brahimi-Horn C. and Pouyssegur J. (2006). The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull. Cancer 93, E73-E80.
6. Brem S., Cotran R. and Folkman J. (1972). Tumor angiogenesis: a quantitative method for histologic grading. J. Natl. Cancer Inst. 48, 347-356.
7. Busam K.J., Berwick M., Blession K., Fandrey K., Kang S., Karaoli T., Fine J., Cochran A.J., White W.L. and Rivers J. (2005). Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am. J. Pathol. 147, 1049-1056.
8. Cantu De Leon D., Lopez-Graniel C., Frias Mendivil M., Chanona Vilchis G., Gomez C. and De La Garza Salazar J. (2003). Significance of microvascular density (MDV) in cervical cancer recurrence. Int. J. Gynecol. Cancer 13, 856-862.
9. Cernea C.R., Ferraz A.R., de Castro I.V., Sotto M.N., Logullo A.F., Bacchi C.E. and Potenza A.S. (2004). Angiogenesis and skin carcinomas with skull base invasion: a case-control study. Head Neck 26, 396-400.
10. Chalkley H.W. (1943). Method for the quantitative morphologic analysis of tissues. J. Natl. Cancer Inst. 4, 47-53.
11. Chandrachud K.M., Pendleton N., Chisholm D.M., Horan M.A. and Schor A.M. (1997). Relationship between vascularity, age and survival in non-small-cell lung cancer. Br. J. Cancer 76, 1367-1375.
12. Cooney M.M., van Heeckeren W., Bhakta S., Ortiz J. and Remick S.C. (2006). Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat. Clin. Pract. Oncol. 3, 682-692.
13. Couvelard A., O'Toole D., Turley H., Leek R., Sauvanet A., Degott C., Ruszniewski P., Belghiti J., Harris A.L., Gatter K. and Pezzella F. (2005). Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 92, 94-101.
14. Dales J.P., Garcia S., Carpentier S., Andrac L., Ramuz O., Lavaut M.N., Allasia C., Bonnier P. and Charpin C. (2004a). Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum. Pathol. 35, 176-183.
15. Dales J.P., Garcia S., Carpentier S., Andrac L., Ramuz O., Lavaut M.N., Allasia C., Bonnier P. and Taranger-Charpin C. (2004b). Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br. J. Cancer 90, 1216-1221.
16. de Jong J.S., van Diest P.J. and Baak J.P.A. (1995). Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab. Invest. 73, 992-996
17. DeYoung B., Wick M.R., Fitzgibbon J.F., Sirgi K.E. and Swanson P.E. (1993). CD31: an immunospecific marker for endothelial differentiation in human neoplasms. Appl. Immunohistochem. 1, 97-100.
18. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H. and Augustin H.G. (2000). Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388-1393.
19. Fernandez-Aguilar S., Jondet M., Simonart T. and Noel J.C. (2006). Microvessel and lymphatic density in tubular carcinoma of the breast: comparative study with invasive low-grade ductal carcinoma. Breast 15, 782-785.
20. Fox S.B. (1997). Tumour angiogenesis and prognosis. Histopathology 30, 294-301.
21. Fox S.B., Leek R.D., Smith K., Hollyer J., Greenall M. and Harris A.L. (1994). Tumor angiogenesis in node-negative breast carcinomas. Relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res. Treat. 29, 109-116.
22. Gordan J.D. and Simon M.C. (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 17, 71-77.
23. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W. and Giaccia A.J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91.
24. Gruber M. and Simon M.C. (2006). Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr. Opin. Hematol. 13, 169-174.
25. Hansen S., Grabaud D.A., Rose C., Bak M. and Sorensen F.B. (1998). Angiogenesis in breast cancer. A comparative study of the observer variablity of methods for determining microvessel density. Lab. Invest. 78, 1563-1573.
26. Hansen S., Grabaud D.A., Sorensen F.B., Bak M., Vach W. and Rose C. (2000). The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin. Cancer Res. 6, 139-146.
27. Hickey M.M. and Simon M.C. (2006). Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr. Top. Dev. Biol. 76, 217-257.
28. Hillen F., van de Winkel A., Creytens D., Vermeulen A.H. and Griffioen A.W. (2006). Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res. 16, 453-457.
29. Hlatky L., Hahnfeldt P. and Folkman J. (2002). Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94, 883-893.
30. Korkolopoulou P., Apostolidou E., Pavlopoulos P.M., Kavantzas N., Vyniou N., Thymara I., Terpos E., Patsouris E., Yataganas X. and Davaris P. (2001). Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 15, 1369-1376.
31. Korkolopoulou P., Viniou N., Kavantzas N., Patsouris E., Thymara I., Paulopoulos P.M., Terpos E., Stamatopoulos A., Plata E., Anargyrou K., Androulaki A., Davaris P. and Yataganas X. (2003). Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 17, 89-97.
32. Korkolopoulou P., Thymara I., Kavantzas N., Vassilakopoulos T.P., Angelopoulou M.K., Kokoris S.I., Dimitriadou E.M., Siakantaris M.P., Anargyrou K., Panayiotidid P., Tsenga A., Androulaki A., Doussis-Anagnostopoulou I.A., Patsouris E. and Pangalis G.A. (2005). Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 19, 894-900.
33. Kumar S., Ghellal A., Li C., Byrne G., Haboubi N., Wang J.M. and Bundred N. (1999). Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 59, 856-861.
34. Kusamura S., Derchain S., Alvarenga M., Gomes C.P., Syrjanen K.J. and Andrade L.A. (2003). Expression of p53, c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary. Int. J. Gynecol. Cancer 13, 450-457.
35. Lackner C., Jukic Z., Tsybrovskyy O., Jatzko G., Wette V., Hoefler G., Klimpfinger M., Denk H. and Zatloukal K. (2004). Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch. 445, 160-167.
36. Laquente B., Vinals F. and Germa J.R. (2007). Metronomic chemotherapy: an antiangiogenic scheduling. Clin. Transl. Oncol. 9, 93-98.
37. Lehr H.A., Mankoff D.A., Corwin D., Santeusanio G. and Gown A.M. (1997). Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J. Histochem. Cytochem. 45, 1559-1565.
38. Lenz H.J. (2005). Antiangiogenic agents in cancer therapy. Oncology (Williston Park) 19, 17-25.
39. Lindmark G., Gerdin B., Sundberg C., Pahlman L., Bergstrom R. and Glimelius B. (1996). Prognostic significance of the microvascular count in colorectal cancer. J. Clin. Oncol. 14, 461-466.
40. Lundberg L.G., Hellstrom-Lindberg E., Kanter-Lewensohn L., Lerner R. and Palmblad J. (2006). Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk. Res. 30, 247-253.
41. Mabjeesh N.J. and Amir S. (2007). Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol. Histopathol. 22, 559-572.
42. Marioni G., Gaio E., Giacomelli L., Marchese-Ragona R., Staffieri C., Staffieri A. and Marino F. (2005). Endoglin (CD105) expression in head and neck basaloid squamous cell carcinoma. Acta Otolaryngol. 125, 307-311.
43. Marioni G., Marino F., Giacomelli L., Staffieri C., Mariuzzi M.L., Violino E. and De Filippis C. (2006). Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol. 126, 633-639.
44. Marrogi A.J., Travis W.D., Welsh J.A., Khan M.A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N.E., Liotta L.A. and Harris C.C. (2000). Nitric Oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin. Cancer Res. 6, 4739-4744.
45. Mikhail M.S., Palan P.R., Basu J. and Romney S.L. (2004). Computerized measurement of intercapillary distance using image analysis in women with cervical intraepithelial neoplasia: correlation with severity. Acta Obstet. Gynecol. Scand. 83, 308-310.
46. Minhajat R., Mori D., Yamasaki F., Sugita Y., Satoh T. and Tokunaga O. (2006). Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. Virchows Arch. 448, 127-134.
47. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., Nishimura S., Imamura Y., Kitayama H., Alexander D.B., Ide C., Horan T.P., Arakawa T., Yoshida H., Nishikawa S., Itoh Y., Seiki M., Itohara S., Takahashi C. and Noda M. (2001). The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789-800.
48. Rhee J. and Hoff P.M. (2005). Angiogenesis inhibitors in the treatment of cancer. Expert Opin. Pharmacother. 6, 1701-1711.
49. Ribatti D. and Ponzoni M. (2005). Antiangiogenic strategies in neuroblastoma. Cancer Treat. Rev. 31, 27-34.
50. Ribatti D., Vacca A. and Dammacco F. (2003). New non-angiogenesis dependent pathways for tumour growth. Eur. J. Cancer 39, 1835-1841.
51. Ribatti D., Vacca A., Nico B., Sansonno D. and Dammacco F. (2006). Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat. Rev. 32, 437-444.
52. Ridell B. and Norrby K. (2001). Intratumoral microvascular density in malignant lymphomas of B-cell origin. APMIS 109, 66-72.
53. Sandlund J., Hedberg Y., Bergh A., Grankvist K., Ljungberg B. and Rasmuson T. (2006). Endoglin (CD105) expression in human renal cell carcinoma. BJU Int. 97, 706-710.
54. Schoell W.M., Pieber D., Reich O., Lahousen M., Janicek M., Guecer F. and Winter R. (1997). Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis. Cancer 80, 2257-2262.
55. Sharma S., Sharma M.C., Gupta D.K. and Sarkar C. (2006). Angiogenic patterns and their quantitation in high grade astrocytic tumors. J. Neurooncol. 79, 19-30.
56. Shimizu T., Hino K., Tauchi K., Ansai Y. and Tsukada K. (2000). Prediction of axilary lymph node matastasis by intravenous digital substraction angiography in breast cancer, its correlation with microvascular density. Breast Cancer Res. Treat. 61, 261-269.
57. Simpson J.F., Ahn C., Battifora H. and Esteban J.M. (1996). Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 77, 2077-2085.
58. Singhal S., Mehta J., Desikan R., Ayers D., Robertson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J. and Barlogie B. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571.
59. Srivastava A., Laidler P., Davies R., Horgan K. and Hughes L.E. (1988). The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. Am. J. Pathol. 133, 419-423.
60. Steinberg F., Rohrborn H.J., Otto T., Scheufler K.M. and Streffer C. (1997). NIR reflection measurements of hemoglobin and cytochrome aa3 in healthy tissue and tumors. Correlation to oxygen consumption: preclinical and clinical data. Adv. Exp. Med. Biol. 428, 69-77.
61. Thomlinson R.H. and Gray L.H. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9, 539-549.
62. Thorpe P.E., Derbyshire E.J., King S.W. and Burrows F.J. (1994). Targeting the vasculature of carcinoma and other solid tumors. Proc. Am. Assoc. Cancer Res. 35, 379 (Abstr 2260).
63. Traweek S.T., Kandalaft P.L., Mehta P. and Battifora H. (1991). The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am. J. Clin. Pathol. 96, 25-31.
64. Turner H.E., Nagy Z., Gatter K.C., Esiri M.M., Harris A.L. and Wass J.A. (2000). Angiogenesis in pituitary adenomas and the normal pituitary gland. J. Clin. Endocrinol. Metab. 85, 1159-1162.
65. Vacca A. and Ribatti D. (2006). Bone marrow angiogenesis in multiple myeloma. Leukemia 20, 193-199.
66. Van de Rijn M. and Rouse R.V. (1994). CD34: a review. Appl. Immunohistochem. 2, 71-80.
67. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., Mc Culloch P., Pezzella F., Viale G., Weidner N., Harris A.L. and Dirix L.Y. (1996). Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 32A, 2474-2484.
68. Vermeulen P.B., Libura M., Libura J., O'Neill P.J., van Dam P., Van Marck E., Van Oosterom A.T. and Dirix L.Y. (1997). Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res. Treat. 42, 165-172.
69. Wang J.M., Kumar S., Pye D., Van Agthoven A.J., Krupinski J. and Hunter R.D. (1993). A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int. J. Cancer 54, 363-370.
70. Wang J.M., Kumar S., Pye D., Haboubi N. and Al-Nakib L. (1994). Breast carcinoma: comparative study of tumor vaculature using two endothelial cell markers. J. Natl. Cancer Inst. 86, 386-388.
71. Weidner N., Sample J.P., Welch W.R. and Folkman J. (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1-8.
72. Weidner N., Carroll P.R., Flax J., Blumenfeld W. and Folkman J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401-409.
73. Yao X., Qian C.N, Zhang Z.F., Tan M.H., Kort E.J., Yang X.J., Resau J.H. and Teh B.T. (2007). Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin. Cancer Res. 13, 161-169.
74. Yoshii Y. and Sugiyama K. (1988). Intercapillary distance in the proliferating area of human glioma. Cancer Res. 48, 2938-2941.
75. Yue W.Y. and Chen Z.P. (2005). Does vasculogenic mimicry exist in astrocytoma? J. Histochem. Cytochem. 53, 997-1002.
76. Zhang S., Zhang D. and Sun B. (2007). Vasculogenic mimicry: Current status and future prospects. Cancer Lett. (in press).
77. Zhao Z.S., Zhou J.L., Yao G.Y., Ru G.Q., Ma J. and Ruan J. (2005). Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J. Gastroenterol. 11, 3227-3233.
78. Zhong H. and Bowen J.P. (2006). Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr. Med. Chem. 13, 849-862.